Target intelligence / Profile preview

HIV-1 Gag major homology region (MHR)

Target
MHR
Molecular classification
Viral structural protein domain, Capsid protein domain, Protein-protein interaction motif
01

Overview

The HIV-1 Gag major homology region (MHR) is a highly conserved 20-amino acid sequence located within the C-terminal domain (CTD) of the capsid (CA) protein (UniProt: P04591). This motif is nearly universal among orthoretroviruses, suggesting a fundamental role in the viral life cycle and structural integrity (PubMed: 8120549). Biologically, the MHR is essential for the proper assembly of the immature Gag polyprotein lattice and the subsequent formation of the mature, infectious viral core during the budding process (PubMed: 15564416). Mutations within the MHR typically result in severe assembly defects, leading to the production of non-infectious, morphologically aberrant virions or a complete failure in particle release (PubMed: 9223631). Due to its high degree of conservation and critical structural function, the MHR is a significant target for the development of capsid assembly inhibitors (PubMed: 27129250). Therapeutic interventions targeting this region, such as experimental peptides and small molecules, aim to disrupt the protein-protein interactions necessary for viral replication. While clinical capsid inhibitors like Lenacapavir target broader interfaces, the MHR remains a focal point for research into next-generation antiretroviral therapies.

Other names
Gag MHRCapsid major homology regionCA MHRMajor homology region of HIV-1 Gag
02

Mechanism of action

Inhibition of Gag multimerization and viral capsid assembly by disrupting protein-protein interactions within the major homology region, preventing the formation of infectious virions.

03

Biological functions

Viral assemblyCapsid dimerizationViral maturationGag polyprotein multimerizationIntracellular Gag trafficking
04

Disease associations

HIV-1 infectionAcquired immunodeficiency syndrome (AIDS)
05

Safety considerations

Emergence of drug-resistant mutations in the CA domainPotential for low genetic barrier to resistance in highly specific motifsLong-term safety of capsid-targeting agents
06

Interacting drugs

Lenacapavir

4 more in the full profile.

07

Biomarkers

HIV-1 RNA viral load (plasma)CD4+ T-lymphocyte countGag polyprotein processing levels (experimental)

Beyond the preview

Go deeper on HIV-1 Gag major homology region (MHR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV-1 Gag major homology region (MHR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call